The response to the COVID-19 pandemic has put the UK Government and NHS on an emergency footing. With this substantial change to NHS services, there has been a rapid growth in published guidelines and policy to help Healthcare Professionals (HCPs) ensure patients get the right treatment and care. Here we have detailed some key sources of information and the more important guidelines that will affect the myeloma community.
Myeloma Specific Guidelines and Information
Information specifically related to myeloma and COVID-19.
UK Myeloma Society COVID-19 guidance
UK Myeloma Society Interim treatment change options for the COVID-19 endorsed by NHS England
Myeloma UK COVID-19 information hub
Cancer Treatment and Care Guidelines
Information relating to the management of cancer treatment and care during the COVID-19 pandemic.
England, Wales and Northern Ireland
NHS England advice for clinicians: Cancer
National Institute of Health and Care Excellence (NICE) Coronavirus (COVID-19) hub
NICE COVID-19 rapid guideline: delivery of systemic anticancer treatments
Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England
COVID-19 rapid guideline: haematopoietic stem cell transplantation
COVID-19 rapid guideline: delivery of radiotherapy
Scotland
Guidelines for cancer treatment during COVID-19 pandemic
Resources for NHS Scotland in the COVID-19 pandemic
COVID-19 (Coronavirus) and Cancer: Information if you are a patient or carer
General COVID 19 Guidelines
UK Government Coronavirus Guidance including links to Scotland, Wales and Northern Ireland information hubs.
Myeloma patients, including those in remission, were specifically referenced as being extremely vulnerable to COVID-19 and were advised to shield.
Advice for England, Wales and Northern Ireland
Guidance and Information from professional organisations
Including advice on vaccinations.
British Society of Haematology (BSH) COVID-19 Updates
Royal College of GP’s Latest COVID-19 guidance
Royal College of Nursing COVID-19 (coronavirus)
European Society of Medical Oncology (ESMO) COVID-19: supporting oncology professionals